Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03880253 · ClinicalTrials.gov registry record · Phase 1
Multiple Ascending Dose Study of CTP-692 in Healthy Volunteers
A Phase 1 study, sponsored by Concert Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT03880253 is a Phase 1 study that has completed, run by Concert Pharmaceuticals. The registered enrollment target is 30 participants.
The verdict
NCT03880253, a Phase 1 study, has completed, sponsored by Concert Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This study will assess in healthy male and female subjects the safety and pharmacokinetic (PK) profiles of 3 dose levels of CTP-692 following 7 days of dosing.
Interventions
- DRUG CTP-692
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2019-04-10 |
| Est. Completion | 2019-05-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03880253
The ClinicalTrials.gov registry entry for NCT03880253 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Concert Pharmaceuticals, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CTP-692 is the first listed.
NCT03880253 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03880253 about?
NCT03880253 is a clinical study titled "Multiple Ascending Dose Study of CTP-692 in Healthy Volunteers". This study will assess in healthy male and female subjects the safety and pharmacokinetic (PK) profiles of 3 dose levels of CTP-692 following 7 days of dosing.
What is the current status of trial NCT03880253?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2019-04-10. Estimated completion is 2019-05-16.
What interventions are being tested in trial NCT03880253?
The interventions under investigation include: CTP-692 (DRUG).
Who is sponsoring clinical trial NCT03880253?
This trial is sponsored by Concert Pharmaceuticals, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.